Skip to content Skip to footer
Subscribe Now
TOP 20

Top 20 Radiopharmaceutical Companies of 2026

Shots:  The Top 20 Radiopharma Companies of 2026, ranked by market capitalization, represent a powerful mix of global pharmaceutical leaders and agile innovators transforming radioligand therapies, alpha-emitters, and copper-based theranostics into pillars of modern oncology. What was once niche science is now redefining precision cancer care.  Flagship therapies such as Lutathera, Pluvicto, Pylarify, Illuccix/Gozellix, Xofigo,…
February 27, 2026

Read more

Radiopharma Companies Top 20 2025
TOP 20

Top 20 Radiopharmaceutical Companies of 2025

Shots: Imaging, precision diagnostics, and targeted therapies are among the many ways radiopharmaceuticals improve patient outcomes and meet unmet healthcare needs In 2024, the global radiopharmaceuticals market was valued at $6.74B and is envisioned to grow to $13.67B by 2033, exhibiting a CAGR of 8.2% from 2024 to 2033. Lilly ranks first in our list…
March 27, 2025

Read more

Radiopharma Top 20 2022
TOP 20

Top 20 Radiopharma Companies Based on Market Cap

Shots: Integrating scintigraphy with therapeutics, radiopharmaceutical companies have emerged profoundly in the past few decades. With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market With the expanding acceptance among HCPs, patients, and researchers, radiopharmaceutical companies are estimated to touch the $7.5B threshold by 2026. This year,…
February 21, 2023

Read more

Life Sciences Top 20 2022
TOP 20

Top 20 Life Sciences Deals of 2022 by Total Deal Value

Shots: The technological advancement, shared cost, and the pursuit of combined extensive research are amongst the few pragmatic and mutual benefits that come with collaborations. Moreover, the risks involved in drug development plans get minimalized by opening the doors to new opportunities and commercialization When it comes to life science collaborations, companies seek beyond the…
February 8, 2023

Read more

Life Sciences Deals Top 20 2021
TOP 20

Top 20 Life Sciences Deals of 2021 by Total Deal Value

Shots: The life science industry saw high deal activity in 2021 staying in the range of an even busier 2020. Fourth-quarter 2021 set the tone with Recursion’s development and commercialization deal with Roche and Genentech for a total value of $12.7B, followed by Poseida Therapeutics’ development and commercialization deal with Takeda for $3.73B. This article is based on the 2021…
February 10, 2022

Read more

Viewpoints_Thierry Abribat
VIEWPOINTS

PharmaShots Interview: Amolyt Pharma’s Thierry Abribat Shares Insight on AZP-3601 for Hypoparathyroidism

In an interview with PharmaShots, Thierry Abribat, Founder and Chief Executive Officer of Amolyt Pharma share his views on the clinical profile of AZP-3601. He also shed light on how it differs from other treatments in development for hypoparathyroidism. Shots: Amolyt Pharma presented positive data from the single ascending dose (SAD) portion of its Ph1 study evaluating AZP-3601…
May 10, 2021

Read more